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t is assumed that the survival factors Bcl-2 and Bcl-x
 
L
 
 are
mainly functional on mitochondria and therefore must
contain mitochondrial targeting sequences. Here we
show, however, that only Bcl-x
 
L
 
 is speciﬁcally targeted to
the mitochondrial outer membrane (MOM) whereas Bcl-2
distributes on several intracellular membranes. Mitochondrial
 
targeting of Bcl-x
 
L
 
 requires the COOH-terminal trans-
membrane (TM) domain ﬂanked at both ends by at least
two basic amino acids. This sequence is a bona ﬁde targeting
signal for the MOM as it confers speciﬁc mitochondrial local-
I
 
ization to soluble EGFP. The signal is present in numerous
proteins known to be directed to the MOM. Bcl-2 lacks the
signal and therefore localizes to several intracellular
membranes. The COOH-terminal region of Bcl-2 can be
converted into a targeting signal for the MOM by increasing
the basicity surrounding its TM. These data deﬁne a new
targeting sequence for the MOM and propose that Bcl-2
acts on several intracellular membranes whereas Bcl-x
 
L
 
speciﬁcally functions on the MOM.
 
Introduction
 
The Bcl-2 family of proteins are central regulators of apoptosis
because they integrate diverse survival and death signals that
are generated outside and inside the cell (Cory and Adams,
2002). The family is subdivided into two classes, anti-apoptotic
 
members such as Bcl-2 and Bcl-x
 
L
 
 (Bcl-2-like survival factors),
which protect cells from apoptosis, and pro-apoptotic members
such as Bax and Bak (Bax-like death factors) and the BH3-
only death proteins, which trigger or sensitize cells for
apoptosis (Antonsson, 2001; Puthalakath and Strasser, 2002).
An important, although not exclusive, action of Bcl-2 family
members is to control mitochondrial membrane permeability.
In response to various apoptotic stimuli, the mitochondrial
outer membrane (MOM)* is perforated without disrupting
the general integrity of the organelle (von Ahsen et al.,
2000). As a consequence, proteins that are safely sequestered
in the mitochondrial intermembrane space in healthy cells,
leak into the cytoplasm where they participate in caspase-
dependent and -independent apoptosis signaling (Desagher
and Martinou, 2000).
Whereas Bax-like factors increase mitochondrial perme-
ability,  Bcl-2–like factors block this process (Antonsson,
2001; Cory and Adams, 2002). The two protein classes can
neutralize each other by heterodimerization but this does not
entirely explain their function (Knudson and Korsmeyer,
1997). Recent studies showed that the BH3-only proteins are
required for the apoptotic regulation of Bcl-2– and Bax-like
factors (Puthalakath and Strasser, 2002). These proteins act
as “sensors” for apoptotic stimuli at different locations within
the cells. In response to a defined stimulus, a particular BH3-
only protein is modified by proteolysis or posttranslational
modification, leaves its intracellular site, and travels to the
mitochondrial membrane where it can choose two fates. Either
it interacts, via its BH3 domain, with Bcl-2–like survival factors
to release a pro-apoptotic protein, or it interacts with Bax-like
factors to stimulate their oligomerization and/or membrane
insertion. In both cases, Bax and Bak are activated to trigger
MOM perforation by a mechanism that has yet to be identi-
 
fied. On the other hand, Bcl-2 and Bcl-x
 
L
 
 inhibit cell death
when sufficiently expressed to sequester BH3-only proteins,
Bax-like factors, and other pro-apoptotic molecules (Cory
and Adams, 2002).
It is thought that Bcl-2 and Bcl-x
 
L
 
 are redundant in their
capacity to protect cells from apoptosis (Chao et al., 1995).
Both proteins block BH3-only and Bax/Bak-mediated
MOM perforation and may therefore primarily function
on mitochondria. However, Bcl-2 also localizes to the nuclear
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envelope and the membrane of the ER (Krajewski et al.,
1993; Givol et al., 1994; Janiak et al., 1994; Lithgow et al.,
1994; Conus et al., 2000b), where it can theoretically se-
quester pro-apoptotic molecules in a similar way as on mi-
tochondria. Indeed, if Bcl-2 is artificially targeted to the
ER, it still protects cells from apoptosis (Zhu et al., 1996;
Hacki et al., 2000). A recent study revealed that specific
targeting of Bcl-2 to mitochondria converts it into a pro-
apoptotic molecule (Wang et al., 2001), suggesting that
mitochondria may not be the preferred site for the survival
action of Bcl-2.
Both Bcl-2 and Bcl-x
 
L
 
 are tail-anchored proteins, i.e., they
contain a COOH-terminal hydrophobic helix that functions
as a membrane insertion device (transmembrane [TM] do-
main) (Chen-Levy and Cleary, 1990; Nguyen et al., 1993;
Janiak et al., 1994; Kim et al., 1997). Proteins that are tail
anchored to the MOM or the ER, such as the MOM trans-
locases TOM22 (Egan et al., 1999) and TOM5 (Horie et
al., 2002) or the microsomal form of cytochrome b5 (De
Silvestris et al., 1995), use their TM anchor also as a target-
ing signal. Although targeting signals for the translocation of
proteins across the ER membrane or the inner mitochon-
Figure 1. Bcl-xL and Bcl-xS specifically localize 
to the MOM, whereas Bcl-2 resides on several 
membranes. (A) Anti–Bcl-2 and anti–Bcl-x 
Western blots of subcellular fractions from 
parental HEK 293 cells (endo) or HEK293 cells 
transiently overexpressing Bcl-2, Bcl-xL, or 
FLAG–Bcl-xS (exo). The mitochondrial fraction 
was obtained from the 1.4 M band and the 
heavy microsomal fraction from the 1.0 M 
band of the sucrose gradient (see Materials and 
methods). Light microsomes are the pellet of 
the 100,000 g spin. Purity of the fractions was 
checked with anti-grp78/Bip and anti-KDEL (microsomes) and anti–COX-VIc (mitochondria) antibodies. TAP(I-VI)–EGFP contains the first six 
membrane-spanning regions of the antigen peptide transporter I (TAP I) fused to EGFP. This protein specifically spans the ER membrane and 
is detected by anti-GFP Western blotting after transient transfection. (B) Anti–Bcl-x Western blots of mitochondrial matrix, inner membrane 
(mb), and outer membrane fractions of rat liver, HEK293 cells, and HEK293 cells transiently overexpressing Bcl-xL (HEK293/Bcl-xL). (C) Anti–Bcl-2 
and anti–Bcl-x Western blots of mitochondria or microsomes from parental HEK293 cells or HEK293 cells overexpressing Bcl-2 or Bcl-xL or 
FLAG–Bcl-xS, extracted directly with detergent (total) or first treated with sodium carbonate (pH 12, peripheral) and then extracted with 
detergent (integral). (D) Autoradiography of [
35S]methionine-labeled, in vitro–transcribed/translated (IVTT) Bcl-2, Bcl-xL, or FLAG–Bcl-xS 
inserted (alkali resistant, integral) or loosely attached (alkali extractable, peripheral) to mitochondria or microsomes (pellet), or remaining in 
the supernatant after spinning off the organelles. (E) Anti–Bcl-2 and anti–Bcl-x immunofluorescence analysis of R6 cells transiently overexpressing 
Bcl-xL, FLAG-Bcl-xS, or Bcl-2 (green). Whereas both Bcl-xL and FLAG–Bcl-xS colocalize with the mitochondrial marker cytochrome c (Cyt.c, red), 
Bcl-2 colocalizes with the ER marker calnexin (red). Nuclei were stained with Hoechst 33342 (blue in the merge).T
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drial membrane are well known (Neupert, 1997), those that
target proteins to the MOM have only recently begun to be
unveiled. A putative targeting signal for the MOM may be a
hydrophobic TM region with a particular length and hydro-
phobicity followed by one to two basic amino acids (TMB)
(Mihara, 2000; Wattenberg and Lithgow, 2001). As both
Bcl-2 and Bcl-x
 
L
 
 contain one to two basic amino acids after
their TM region, it was proposed that they are both targeted
to the MOM (Kuroda et al., 1998; Everett et al., 2000).
However, localization studies have been mostly performed
under nonphysiological conditions where Bcl-2 and Bcl-x
 
L
 
were overexpressed. It has therefore remained elusive whether
endogenous Bcl-2 and Bcl-x
 
L
 
 distribute evenly or are specifi-
cally targeted to the MOM. Moreover, there has not been a
systematic analysis on the signal sequence that directs these
proteins to organelles.
Here we perform an extensive mutagenesis analysis in the
COOH terminus of Bcl-2 and Bcl-x
 
L
 
. We show that Bcl-x
 
L
 
contains a particular mitochondrial signal sequence in this
region whereas Bcl-2 does not. This signal requires two basic
amino acids at both ends of the TM domain. Importantly,
we show that not only overexpressed but also endogenous
Bcl-x
 
L
 
 and Bcl-2 localize to different subcellular compart-
ments. It is proposed that Bcl-x
 
L
 
 specifically acts on mito-
chondria whereas Bcl-2 can also control ER events associ-
ated with apoptosis.
 
Results
 
Bcl-x
 
L
 
/x
 
S
 
 are integral proteins of the MOM whereas 
Bcl-2 inserts into several membranes
 
Endogenous and overexpressed Bcl-x
 
L
 
 were enriched in mi-
tochondria when purified subcellular fractions of HEK293
cells were analyzed on anti–Bcl-x immunoblots (Fig. 1 A). A
protein band with a slightly higher molecular mass was de-
tected in the light microsomal fraction of cells overexpress-
ing Bcl-x
 
L
 
 (Fig. 1 A). In certain cell types, Bcl-x
 
L
 
 also ap-
peared in the cytosol, especially when the protein was
overexpressed (unpublished data). Immunoblots with or-
ganelle-specific marker antibodies revealed that the subcellu-
lar fractions were pure (Fig. 1 A). Nuclear fractions are not
shown because they could not be reproducibly deprived of
cosedimenting or aggregated mitochondria and unlysed
cells. A further subfractionation of HEK293 and rat liver
mitochondria showed that the major proportion of Bcl-x
 
L
 
resided in the MOM (Fig. 1 B). Endogenous Bcl-x
 
L
 
 was sta-
bly integrated into the mitochondrial membrane because it
could only be extracted with detergent (integral) (Fig. 1 C).
By contrast, some of the overexpressed Bcl-x
 
L
 
 was loosely
(peripherally) attached to this membrane. When Bcl-x
 
L
 
 was
in vitro transcribed/translated and added to purified mito-
chondria, most of the protein was recovered in the mito-
chondrial pellet in a stably inserted form (Fig. 1 D). The
pro-apoptotic splice variant Bcl-x
 
S
 
, which is identical to Bcl-
x
 
L
 
 but lacks the BH1/BH2 regions (Boise et al., 1993), also
accumulated in mitochondria after ectopic expression in
HEK293 cells (Fig. 1 A) and in vitro translation (Fig. 1 D)
and inserted even better into the mitochondrial membrane
than Bcl-x
 
L
 
 (Fig. 1 C). The endogenous Bcl-x
 
S
 
 protein could
 
not be studied because it was not expressed at detectable lev-
els in 10 different cell lines (unpublished data). Strikingly, in
contrast to Bcl-x
 
L
 
 and Bcl-x
 
S
 
, endogenous and overexpressed
Bcl-2 were found in all intracellular membrane fractions
(Fig. 1 A). The mitochondrial portion of Bcl-2 may be even
overestimated, as some heavy microsomal membranes could
not be entirely separated from mitochondria, as evidenced
by the ER membrane–specific marker TAP(I-VI)–EGFP
(Vos et al., 2000) (Fig. 1 A). This fraction did not contain
the luminal grp78/Bip and KDEL proteins and may consist
of microsomal membranes that are fused to mitochondria as
recently proposed (Landolfi et al., 1998; Prinz et al., 2000).
Bcl-2 integrated into the microsomal membrane in a similar
way as Bcl-x
 
L
 
 integrated into mitochondria. Although en-
dogenous Bcl-2 was never cytosolic and stably inserted into
membranes (Fig. 1, A and C), some of the overexpressed
form loosely attached to microsomes (Fig. 1 C) and re-
mained in the supernatant after in vitro transcription/trans-
lation (Fig. 1 D). Immunofluorescence analysis of R6 (Fig. 1
E) or HeLa cells (unpublished data) confirmed our in vitro
data. Whereas Bcl-2 colocalized with the ER protein cal-
nexin on nuclear/ER membrane structures, Bcl-x
 
L
 
 and Bcl-x
 
S
 
were consistently immunodetected in filamentous structures
that colocalized with the mitochondrial markers TOM20,
COX, or cytochrome c (Fig. 1 E). Our data show that Bcl-
x
 
L
 
/x
 
S
 
 and Bcl-2 are primarily membrane-inserted proteins,
but with different targeting specificities.
 
The TMB region is important for the membrane 
targeting of Bcl-x
 
L
 
/x
 
S
 
 and Bcl-2
 
What determines the specific targeting of Bcl-x
 
L
 
/x
 
S
 
 to the
MOM and why is Bcl-2 incapable of doing so? Targeting
sequences for the MOM have recently been identified in
proteins of the TOM complex, monoamine oxidase A/B,
VAMP-1B, and members of the Bcl-2 family (for reviews see
Mihara, 2000; Wattenberg and Lithgow, 2001). These se-
quences are present at either the NH
 
2
 
 or COOH termini of
the proteins and consist of a hydrophobic, 
 
 
 
-helical TM re-
gion followed by one or two basic amino acids (TMB). Both
Bcl-x
 
L
 
/x
 
S
 
 and Bcl-2 contain a typical TMB domain at their
COOH terminus (Fig. 2 A). To investigate the role of the
TMB of Bcl-x
 
L
 
/x
 
S
 
 and Bcl-2 in (mitochondrial) membrane
targeting, this region was deleted (Fig. 2 B) and the tailless
proteins transiently expressed in R6, HeLa, and HEK293
cells. Bcl-2
 
 
 
TMB, Bcl-x
 
L
 
 
 
TMB, and FLAG-tagged Bcl-x
 
S
 
-
 
 
 
TMB proteins were all immunodetected in cytosolic frac-
tions and exhibited a diffuse cellular staining (Fig. 3, A and
C). For Bcl-2
 
 
 
TMB, we also noticed a staining of the nuclear
envelope (Fig. 3 C), and part of the protein copurified with a
light microsomal fraction (Fig. 3 A). In addition, a portion of
in vitro–translated Bcl-2
 
 
 
TMB was recovered in the pellet af-
ter incubation with microsomes (Fig. 3 B). However, the pro-
tein was only peripherally attached to membranes (Fig. 3 A),
indicating that its membrane association was possibly a side
effect of overexpression. Bcl-x
 
L
 
 
 
TMB and FLAG–Bcl-x
 
S
 
-
 
 
 
TMB were even less detected in membrane fractions than
Bcl-2
 
 
 
TMB (Fig. 3, A and B), and the type of membrane
was microsomal rather than mitochondrial, indicating that
the tailless proteins lacked specific MOM targeting (Fig. 3 A).T
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These data suggest that the TMB region is crucial for effective
membrane insertion of all three proteins.
 
The TMB of Bcl-x requires the preceding X domain 
for effective membrane insertion and 
mitochondrial targeting
 
To investigate whether the TMBs of Bcl-2 and Bcl-x
 
L
 
/x
 
S
 
 alone
were sufficient for membrane targeting, they were separately
fused to the COOH-terminal end of EGFP (Fig. 2 C). To
our surprise, both the EGFP–TMB(Bcl-2) and EGFP–
TMB(Bcl-x) proteins displayed a diffuse staining by whole
cell fluorescence and mainly localized to a cytosolic fraction
(Fig. 4, A and B), suggesting a role for additional amino acid
sequences in Bcl-x and Bcl-2 for membrane targeting. The re-
gion preceding the TMBs, called the X domain, has no se-
quence homology between Bcl-2 and Bcl-x (Fig. 2 A) and
thus could be responsible for the distinct subcellular targeting
of the two proteins. Introduction of the X domain of Bcl-x
into the EGFP–TMB(Bcl-x) construct (EGFP–X–TMB[Bcl-
x]) or half of the X domain of Bcl-2 (amino acids WLSLK)
into the EGFP–TMB(Bcl-2) construct (EGFP–X/2–
TMB[Bcl-2]) (Fig. 2, A and C) gave identical targeting speci-
ficities as for wild-type Bcl-x
 
L
 
/x
 
S
 
 or Bcl-2, respectively
(compare Fig. 4, A and B, to Fig. 1, A and E). The EGFP–
X/2–TMB(Bcl-2) protein was immunodetected in all mem-
brane fractions and produced a strong nuclear envelope/ER
staining (Fig. 4, A and B). Adding the entire X domain and the
preceding BH2 domain of Bcl-2 (EGFP–BH2X–TMB[Bcl-2])
did not alter its ubiquitous membrane distribution. By con-
Figure 2. Schematic representation of Bcl-2, Bcl-xL, Bcl-xS, their 
mutants, and the EGFP fusion constructs. Schematic structure and 
amino acid sequences of (A) the COOH-terminal parts of wild-type 
Bcl-2 (yellow) and Bcl-xL/xS (blue), including the 19–amino acid-long 
TM domain, flanked by one to two basic amino acids at one end (B) 
and the X or X/2 domain (half of the X domain) at the other end 
(basic amino acids are numbered and indicated in bold); (B) the 
COOH-terminal parts of Bcl-2 and Bcl-xL/xS mutants (point mutations 
and insertions are underlined); (C) the COOH-terminal mutants of 
Bcl-2 and Bcl-x fused to the COOH terminus of EGFP.
Figure 3. Tailless Bcl-xL and Bcl-2 mutants are cytoplasmic and 
partially attached to light microsomes. (A) Anti–Bcl-2 and anti–Bcl-x 
Western blots of subcellular fractions from HEK293 cells transiently 
transfected with Bcl-2 or Bcl-xL mutants lacking the last 21 amino 
acids (TMB domain) (Bcl-2 TMB and Bcl-xL TMB). In addition, a 
sodium carbonate (alkali) extraction of microsomes (as described in 
legend to Fig. 1 C) is shown for Bcl-2 TMB in the right panel. 
(B) Autoradiography of the IVTT products of Bcl-2 TMB, Bcl-xL TMB, 
and FLAG–Bcl-xs TMB, bound to microsomes (pellet) or remaining 
in the supernatant after spinning off the microsomes. (C) Anti–Bcl-2 
and anti–Bcl-x immunofluorescence analysis of HeLa cells transiently 
overexpressing the three mutants.T
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trast, the EGFP–X–TMB(Bcl-x) protein was only found in a
mitochondrial fraction (Fig. 4 B) and was specifically targeted
to elongated, mitochondrial structures (Fig. 4 A). Both the
EGFP–BH2X–TMB(Bcl-2) and the EGFP–X–TMB(Bcl-x)
proteins were difficult to extract from membranes by alkali
treatment, indicating that the X domains directed the stable
membrane insertion of the TMBs (Fig. 4 C). Consistent with
a crucial role of the X domain of Bcl-x in mitochondrial tar-
geting, Bcl-x
 
L
 
 lacking this domain (Bcl-x
 
L
 
 
 
X) (Fig. 2 B) was
found to reside majorly in the cytosol, despite the fact that it
retained its TMB (Fig. 5 C). These data show that in both
Bcl-2 and Bcl-x, the X domain cooperates with the TMB for
membrane association and stable insertion. In Bcl-x, it addi-
tionally constitutes a mitochondrial sorting signal.
 
Switching the X-TMB region between Bcl-x and Bcl-2 
alters membrane targeting selectivity
 
If the X-TMB region of Bcl-x is a bona fide mitochondrial
targeting sequence that is absent in Bcl-2, then switching
this region between the two molecules should alter their tar-
geting properties. We assumed that these proteins did not
undergo major conformational changes due to this ex-
change, as their three-dimensional structure is almost iden-
tical (Cory and Adams, 2002). As expected, a Bcl-2
mutant containing the X-TMB domain of Bcl-x (Bcl-2[X-
TMB(Bcl-x)]; Fig. 2 B) was specifically targeted to mito-
chondria (Fig. 5, A and C). On the other hand, Bcl-x
 
L
 
 lost
its specific mitochondrial association and localized to the cy-
toplasm, the nucleus, and other membranes upon acquisi-
tion of the X-TMB region of Bcl-2 (Bcl-x
 
L
 
[X-TMB(Bcl-2)];
Fig. 2 B; Fig. 5 A; unpublished data). Thus, Bcl-2 can be
specifically targeted to mitochondria in the presence of the
X-TMB mitochondrial sorting signal from Bcl-x.
 
The TMB of Bcl-2 can only partially collaborate with 
the X domain of Bcl-x for mitochondrial sorting
 
Considering the possibility that the TMB of Bcl-2 may have
mitochondrial sorting capacity when combined with the
correct X domain, we generated a EGFP fusion protein that
contained the X domain of Bcl-x and the TMB of Bcl-2.
This EGFP–X(Bcl-x)–TMB(Bcl-2) fusion protein was bet-
ter targeted to the mitochondrial fraction (Fig. 4 B) and lo-
Figure 4. Two basic amino acids of the X domain and the TMB of Bcl-x compose a signal that targets EGFP to mitochondria. (A) Whole 
cell GFP fluorescence analysis of R6 cells transiently transfected with EGFP fused to various COOH-terminal mutants of Bcl-x and Bcl-2. The 
amino acid sequences of the mutants are described in Fig. 2 C. The mitochondrial colocalization marker is cytochrome c. Point mutations are 
underlined. (B) Anti-GFP Western blots of subcellular fractions from HEK293 cells expressing the various EGFP mutants. (C) Sodium carbonate 
extraction, as described in legend to Fig. 1 C, of mitochondria or microsomes isolated from HEK cells transfected with three selected EGFP mutants.T
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calized more specifically to mitochondrial structures (Fig. 4
A) than the EGFP–X/2–TMB(Bcl-2) or EGFP–BH2X–
TMB(Bcl-2) constructs (which contained the X domain of
Bcl-2). However, the protein still appeared in heavy mi-
crosomes as well as in the cytosol (Fig. 4 B). Similar results
were obtained when the X(Bcl-x)–TMB(Bcl-2) region was
fused to Bcl-xL (Bcl-xL[X(Bcl-x)–TMB(Bcl-2)]) or to Bcl-2
(Bcl-2[X(Bcl-x)–TMB(Bcl-2)]). The chimeric proteins colo-
calized with mitochondrial markers (yellow in the merge)
and were partially enriched in mitochondrial fractions, but
significant amounts of the proteins resided in other cellular
compartments (punctated green in the merge), such as on
microsomes and in the cytoplasm (Fig. 5, B and C). These
data suggest that although the X domain of Bcl-x can collab-
orate with the TMB of Bcl-2 for mitochondrial targeting, ef-
fective sorting requires the TMB of Bcl-x.
Two basic residues preceding the TMB of Bcl-x 
compose with the TMB a mitochondrial targeting 
signal, but additional basic residues in the X domain 
stabilize the signal
Which amino acids in the X domain of Bcl-x were crucial to
cooperate with the TMB for mitochondrial targeting? Be-
cause this domain contains four basic residues (as compared
with only one in Bcl-2) (Fig. 2 A), the role of these positive
charges was investigated. First, the basic amino acid that lies
closest to the TMB domain (Arg212) was introduced into
the EGFP–TMB(Bcl-x) construct (Fig. 2 C). Compared
with the EGFP–TMB(Bcl-x) protein, which was entirely cy-
tosolic, EGFP–R–TMB(Bcl-x) partially localized to mito-
chondrial structures (Fig. 4 A) and was retained in a mito-
chondrial fraction (Fig. 4 B). However, most of the fusion
protein still resided in the cytosol and on light microsomes
(Fig. 4 B), and its membrane association was rather periph-
eral (Fig. 4 C). This is in agreement with the prominent cyto-
plasmic localization of the Bcl-xL X mutant, which lacked
the X domain but retained Arg212 and the TMB (Fig. 2 B;
Fig. 5 C). Thus, Arg212 was insufficient for specific mito-
chondrial targeting and membrane insertion. The preceding
region was then extended to the next basic residue (Arg209)
(Fig. 2, A and C). The respective EGFP–RFNR–TMB(Bcl-
x) fusion protein displayed a striking mitochondrial localiza-
tion pattern (Fig. 4 A) and predominantly resided in mito-
chondrial membranes in a stably inserted form (Fig. 4 B;
unpublished data). Despite that, a low amount of the protein
remained in cytosolic and microsomal fractions when com-
pared with EGFP–X–TMB(Bcl-x) (Fig. 4 B) or Bcl-xL (Fig. 1
A). Additional amino acids in the X region, in particular the
first two basic residues (Arg204 and Lys205), were studied
for their capacity to assist mitochondrial targeting (Fig. 2 A).
As compared with EGFP–X–TMB(Bcl-x), which was en-
tirely mitochondrial, the EGFP–AAGQERFNR–TMB(Bcl-
x), where Arg204 and Lys205 were mutated to Ala, similarly
appeared in microsomes and the cytosol as EGFP–RFNR–
TMB(Bcl-x) (Fig. 4 B). These results showed that Arg204
and Lys205 of the X domain slightly increased the mitochon-
drial sorting property of RFNR–TMB(Bcl-x). Consistent
with this notion, an EGFP–X–TMB(Bcl-x) fusion protein
Figure 5. Bcl-2 is specifically targeted to mitochondria upon 
acquisition of the X-TMB domain of Bcl-x. (A and B) Anti–Bcl-2 and 
anti–Bcl-x immunofluorescence analysis of HeLa cells transiently 
transfected with Bcl-2 and Bcl-xL chimera that had their X-TMB 
domains exchanged. The mitochondrial colocalization markers are 
cytochrome c or TOM20 as indicated. (C) Anti–Bcl-2 and anti–Bcl-x 
Western blots of subcellular fractions from HEK293 cells expressing 
the various chimeric mutants as well as a mutant of Bcl-xL devoid of 
its X domain (Bcl-xL X). An asterisk denotes the localization of 
endogenous Bcl-xL.T
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that had all basic residues exchanged to alanine (EGFP–
AAGQEAFNA–TMB[Bcl-x]) lost most of its mitochondrial
targeting function and became largely cytosolic (Fig. 4 B). In
summary, although the RFNR sequence is both required and
sufficient to cooperate with the TMB for mitochondrial tar-
geting, Arg204 and Lys205 of the X domain slightly enhance
this targeting.
To prove that the two Arg, and not the Phe/Asn sequence,
in RFNR conferred the mitochondrial signaling, we mu-
tated these amino acids (Fig. 2 C). EGFP fusion proteins
with both Phe and Asn deleted (EGFP–RR–TMB[Bcl-x]) or
exchanged to Ala (EGFP–RAAR–TMB[Bcl-x]) localized to
mitochondria with a similar efficiency as the RFNR con-
struct (Fig. 4, A and B). By contrast, EGFP fusions that
had one or both Arg exchanged to Ala (EGFP–AFNR–
TMB[Bcl-x], EGFP–RFNA–TMB[Bcl-x], and EGFP–
AFNA–TMB[Bcl-x]) lost most of their mitochondrial asso-
ciation and became cytosolic and microsomal (Fig. 4, A and
B; unpublished data). These mutants also showed a cyto-
plasmic clustering (Fig. 4 A) that was lethal to cells 48 h af-
ter transfection (unpublished data). Thus, the two basic resi-
dues, and not the amino acids between these residues, coop-
erate with the TMB of Bcl-x for mitochondrial sorting.
The mitochondrial sorting signal of Bcl-x also requires 
at least two basic residues downstream of the TM
It was striking that the EGFP–AAGQEAFNA–TMB(Bcl-x)
mutant still specifically associated with mitochondria
whereas the EGFP–TMB(Bcl-x) mutant was fully cytosolic
(Fig. 4 B). This suggested that the TMB of Bcl-x had a par-
tial mitochondrial targeting capacity even though the pre-
ceding X domain did not contain the flanking basic amino
acids. The TMB consists of the hydrophobic TM domain
followed by two basic amino acids in the B domain (RK)
(Fig. 2 A). To investigate whether these basic amino acids
played a role in mitochondrial targeting, we mutated them
in a FLAG-tagged version of Bcl-xL (to distinguish the mu-
tants from endogenous Bcl-xL) (Fig. 2 B). FLAG-tagged Bcl-
xL specifically localized to mitochondria like its nontagged
counterpart (Fig. 6 A). By contrast, eliminating one positive
Figure 6. MOM targeting also requires two basic residues downstream of the TM of Bcl-x and Bcl-2 accumulates on mitochondria by 
increasing the basicity surrounding its TM. (A and B) Anti–Bcl-2 and anti–Bcl-x immunofluorescence analysis of HeLa or R6 cells (as indicated) 
transiently transfected with FLAG-tagged Bcl-xL mutants that had their COOH-terminal basic residues exchanged to serines (A) or FLAG-tagged 
Bcl-2 mutants that contained additional basic residues at their COOH termini (B). In addition, the localization of COOH-terminal FLAG-tagged 
Bcl-xL is shown (Bcl-xL–FLAG). The mitochondrial colocalization markers are cytochrome c or TOM20 as indicated. (C) Anti-FLAG Western 
blots of subcellular fractions from HEK293 cells expressing the mutants described under A and B.T
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charge of the B domain by mutating Arg232 or Lys233 to
Ser was sufficient to prevent the specific mitochondrial asso-
ciation of Bcl-xL. Both the FLAG–Bcl-xL(SK) and FLAG–
Bcl-xL(RS) mutants lost most of the mitochondria-specific
localization pattern, stained the nuclear envelope and the ER
membrane (Fig. 6 A), and resided on all intracellular mem-
branes and in the cytosol in a similar way as Bcl-2 (Fig. 6 C).
Moreover, the addition of an eight–amino acid FLAG pep-
tide to the COOH terminus of Bcl-xL (Bcl-xL–FLAG; Fig. 2
B) led to a cytosolic distribution of Bcl-xL (Fig. 6 A), per-
haps by neutralizing the extreme COOH-terminal RK
amino acids. These data show that the mitochondrial sorting
signal of Bcl-x does not only require two basic residues up-
stream (in the X domain) but also at least two basic residues
downstream of its TM.
Bcl-2 can be specifically sorted to mitochondria by 
increasing COOH-terminal basicity
Based on the Bcl-x results, we reevaluated the mitochondrial
targeting properties of the TMB of Bcl-2. The two COOH-
terminal amino acids in the B domain of Bcl-2 are His-Lys
(HK) instead of Arg-Lys (RK) (Fig. 2 A). Although His is a
basic amino acid, its basicity is weak, and this could be re-
sponsible for the lack of mitochondrial targeting. To investi-
gate this possibility, we mutated His238 to Arg in FLAG-
tagged Bcl-2 (FLAG-Bcl-2[RK]) (Fig. 2 B). As shown in
Fig. 6 B, FLAG–Bcl-2 stained the nuclear envelope and the
associated ER like Bcl-2. This was also the case for FLAG–
Bcl-2(RK) (Fig. 6 B) but the mutant was already more
abundant in a mitochondrial fraction (compare Fig. 6 C
with Fig. 1 A). We therefore increased the basicity of the
COOH terminus of Bcl-2 by one more basic amino acid
(HKRK) (FLAG-Bcl-2[HKRK]) (Fig. 2 B). This mutant
was concentrated in a mitochondrial fraction (Fig. 6 C) and
nicely stained mitochondria in both HeLa (Fig. 6 B) and R6
cells (unpublished data), although some cytosolic localiza-
tion remained. These data indicate that the TM region of
Bcl-2 can contribute to mitochondrial targeting, provided
that it is surrounded by sufficient basicity.
Discussion
In this study, a novel COOH-terminal signal sequence for
the specific targeting and stable insertion of Bcl-xL and Bcl-
xS to the MOM was identified. Bcl-2 lacks this signal and
therefore stably inserts into several intracellular membranes
in a relatively nonspecific manner. This subcellular distribu-
tion was seen to occur for endogenous and overexpressed
Bcl-xL/xS and Bcl-2 proteins in at least three different cell
lines by two different techniques.
Figure 7. Schematic representation of MOM- 
and ER-targeted proteins. (A) Amino acid 
sequences of MOM-targeted proteins whose 
COOH termini conform to the possible 
Bx0–9Bx0–2-TM-x0–1Bx0–6B consensus sequence 
or contain a high basicity at one end of their 
TM-like FLAG–Bcl-2(HKRK) (TOM20 and 
Bcl-w). (B) Amino acid sequences of proteins 
that contain only one basic residues at each 
end (Bcl-2 and Mcl-1), or basic residues at 
only one end of the TM and thus localize to 
extra-mitochondrial sites.T
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Recent studies have shown that the targeting of tail- or tip-
anchored proteins to the MOM depends on the length and
hydrophobicity of a TM domain of 17–23 hydrophobic
amino acids and a short hydrophilic sequence rich in basic
residues either before or after the TM domain (McBride et
al., 1992; Kuroda et al., 1998; Egan et al., 1999; Kanaji et
al., 2000; Mihara, 2000; Horie et al., 2002). We however
noted that these proteins contained basic amino acids at both
ends of their TM (Fig. 7 A). Although a targeting role of pos-
itive charges on both sides have recently been suggested for
the M11L protein of myxoma virus and, astonishingly, for
Bcl-2, no mutagenesis analysis was performed to support this
hypothesis (Everett et al., 2000). Here we combined both
whole cell fluorescence and immunoblot analysis of pure or-
ganelle fractions to show that effective targeting of Bcl-x to
the MOM requires at least two basic residues at both ends of
the TM domain. Neither the hydrophobicity nor the length
of the TM domain appear to play any role in targeting, as the
TMs of Bcl-2 and Bcl-x have a similar degree of hydropho-
bicity and length despite different subcellular localizations. It
may however be important at which distance the basic resi-
dues are located with respect to the TM domain, although
this has not yet been directly tested. By comparing the
MOM targeting sequences of several proteins, we propose
that one basic residue is within one or two amino acids of the
COOH and NH2 termini of the TM domain, respectively,
whereas the second basic residue is up to six or nine amino
acids distant from the first (Fig. 7 A). A comparison of the
subcellular localization of the EGFP–RFNR–TMB(Bcl-x),
EGFP–RAAR–TMB(Bcl-x), and EGFP–RR–TMB(Bcl-x)
constructs (Fig. 4) further suggests that in the case of Bcl-x,
the nature and number of the amino acids between the basic
residues do not play a mitochondrial targeting role. On the
basis of these data, a new putative consensus sequence for
MOM signaling/anchoring is proposed in the form of Bx0–
9Bx0–2-TM-x0–1Bx0–6B (where B stands for basic residues and
x for any amino acid). This consensus is fulfilled by numer-
ous proteins that are tail anchored in the MOM, such as the
Bcl-2 family members Bcl-x, Bcl-B, BHRF-EBV, Nip3, Nix,
and CED-9 as well as VAMP-1B, TOM-5, metaxin-1, myx-
oma viral M11L, monoamine oxidase A and B, and mito-
chondrial cytochrome b5 (Fig. 7 A). In the case of TOM20
and the Bcl-2 family member Bcl-w, which are mitochon-
drial proteins but display only one positive charge at one end
of the TM, the other side contains a higher basicity (three to
four basic residues) (Fig. 7 A), as seen with the mitochon-
dria-targeted FLAG–Bcl-2(HKRK) construct (Fig. 6, B and
C). By contrast, a variety of proteins that are targeted to the
ER and other intracellular membranes lack the MOM target-
ing sequence, either because they contain basic residues at
only one end of the TM (VAMP-1A, VAMP-2, VAMP-8,
BET1, syntaxin 1A, microsomal cytochrome b5, and Bcl-2
homologue NR13) or do not have sufficient basicity at both
ends (Bcl-2 and its homologue Mcl-1) (Fig. 7 B). Thus, the
consensus sequence proposed here is more predictive for
MOM sorting than the sequences previously reported. Ex-
ceptions are the pro-apoptotic Bcl-2 family members Bax
and Bak, which contain basic residues only at one end of the
TM but nevertheless localize to the MOM. These proteins
probably require additional cellular factors to unleash the
COOH-terminal mitochondrial targeting signal, which is
folded back into the molecule after synthesis (Suzuki et al.,
2000; unpublished data).
How does this signal sequence find the MOM and tail an-
chor the protein in this membrane? A multistep mechanism
has been proposed in which the MOM-targeted protein first
associates with cytosolic chaperones during or shortly after
translation (Millar and Shore, 1996). The function of the
chaperones is possibly to shield the emergent hydrophobic
COOH terminus from the cytosol until insertion into the
target membrane can be achieved (Egan et al., 1999; Beddoe
and Lithgow, 2002). The chaperone-bound protein may then
be transferred to a hypothetical receptor protein on the mito-
chondrial surface. Finally, the receptor-bound protein is
passed to an insertion complex that accomplishes integration
of the protein into the bilayer. It is unclear at present whether
proteins targeted to the MOM by COOH-terminal signal/
anchors utilize the same import machinery as matrix-directed
proteins (TOM proteins), although there are some sugges-
tions that at least one of these protein components is em-
ployed (Millar and Shore, 1996). Although tip-anchored pro-
teins, such as TOM20, insert into the MOM independent of
import receptors and then assemble into the TOM complex
(Schneider et al., 1991), it is possible that tail-anchored pro-
teins, such as Bcl-xL and Bcl-xS, require specific receptors.
Analysis of the tail-anchored VAMP-1B protein revealed that
association of this protein with the MOM is saturable, which
suggests the existence of a receptor (Lan et al., 2000). In this
study, we detected increasing amounts of Bcl-xL in the cytosol
or supernatant when the protein was gradually overexpressed
in HeLa or R6 cells or given to isolated mitochondria after in
vitro translation. Although this may indicate the presence of a
receptor, trypsin stripping experiments of the mitochondrial
surface have not yet supported this view, at least not for a pro-
tein receptor (unpublished data). As Bcl-xL and Bcl-xs become
stably inserted in the lipid bilayer after targeting (Fig. 1, C
and D), we propose that their interactions with putative re-
ceptors are only transient. This may also account for the in-
teraction of Bcl-2 with TOM20 in yeast, as recently reported
by Motz et al. (2002), although our data do not support such
an interaction as a major determinant in the subcellular local-
ization of Bcl-2 in mammalian cells. We can also exclude that
these mitochondrial receptors are other members of the Bcl-2
family, as interactions between these proteins occur via the
hydrophobic groove (BH1/BH2 domain) or the BH3 do-
main rather than the COOH terminus (Chittenden et al.,
1995; Zha et al., 1996; Sattler et al., 1997).
Kanaji et al. (2000) reported that the TM region of
TOM20 functions by itself as a signal-anchor sequence to
target GFP fusions to the ER. Bcl-2 and Bcl-xL both have a
TM with similar hydophobicity as TOM20. Surprisingly,
however, these hydrophobic TM domains were insufficient
for membrane targeting and insertion. Even the addition of a
basic residue in front of the TMB (EGFP–K–TMB[Bcl-2],
data not shown; or EGFP–R–TMB[Bcl-x], Fig. 4, A and B)
did not majorly enhance membrane targeting, and the small
amount of protein that was membrane associated was loosely
attached. Only when the sequence included the targeting
motif, i.e., either the two basic residues NH2-terminal to the
TMB of Bcl-xL or the X domain ahead of the TMB of Bcl-2,T
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were the respective proteins stably inserted into membranes.
This supports the notion that targeting and anchoring are in-
timately linked, i.e., the same sequence functions as a target-
ing and insertion device (for review see Mihara, 2000).
Quantitative immunoelectron microscopy revealed that,
depending on the cell type, 55–85% of Bcl-2 molecules are
localized to the ER, and the remainder are inserted into the
MOM of mammalian cells (Krajewski et al., 1993; Lithgow
et al., 1994). In yeast, a fusion protein between the last 33
amino acids of Bcl-2 and a reporter protein is even exclu-
sively targeted to the ER (Egan et al., 1999). We were un-
able to find any sequences in Bcl-2 that would target this
protein specifically to any membrane in rat and human cells,
thus excluding the possibility that this protein contains mul-
tiple targeting signals, as had been suggested (Lan et al.,
2000). Moreover, in contrast to other ER-bound proteins
such as VAMP-1A, the binding of Bcl-2 and microsomal cy-
tochrome b5 to ER microsomes has been reported to be
spontaneous and nonsaturable (Kim et al., 1997). This
strongly suggests that Bcl-2 may not be targeted to this
membrane but distributes on all intracellular membranes de-
pending on the kinetic preference for one membrane over
another (Wattenberg and Lithgow, 2001). Nuclear outer
membrane and ER staining of Bcl-2 by immunofluorescence
(Fig. 1 E; Fig. 4 A) may therefore simply reflect the fact that
this endomembrane system has the largest surface in the cell.
It was noticed that the two basic amino acids located after
the TM domain of Bcl-2, His238-Lys239, may not be suffi-
cient for MOM targeting, and that some portion of the pro-
tein may leak out of the mitochondrial transport apparatus,
allowing Bcl-2 to be transported to or associated with the
ER or other membranes (Kuroda et al., 1998). We show
here that this potential “leaking out” can be prevented by in-
creasing the basicity at the COOH terminus. Thus, the
COOH terminus of Bcl-2 can be converted into a signal for
the MOM, but usually acts as a nontargeting device in the
wild-type protein.
An obvious question is whether Bcl-2 and Bcl-xL exert dif-
ferent functions depending on their intracellular site of lo-
calization. When Bcl-2 was specifically targeted to mito-
chondria (e.g., Bcl-2[X-TMB(Bcl-x)]) and tested for its
ability to block staurosporine- or brefeldin A/cycloheximide-
induced apoptosis of HeLa cells, it was found that the anti-
apoptotic activity of the mutant was only slightly reduced
when compared with the wild-type forms (unpublished
data). Similarly, Bcl-xL targeted to the ER via the tail of the
microsomal cytochrome b5 (unpublished data), or Bcl-xL
carrying the COOH terminus of Bcl-2 (Bcl-xL[X-TMB
(Bcl-2)]), exhibited a survival activity that was nearly as effi-
cient as that of the wild-type Bcl-xL. Also, consistent with
previous results (Borner et al., 1994), cytoplasmic mutants
of Bcl-2 and Bcl-xL still possess partial anti-apoptotic activity
although this continued activity may be due to a minor asso-
ciation between the tailless mutants and membranes, as
shown in Fig. 3. Thus, our data support the notion that Bcl-2
and Bcl-xL are exchangeable survival factors that, indepen-
dent of their subcellular localization, repress a common cell
death pathway (Chao et al., 1995). Whereas previous reports
have proposed nonredundant functions of Bcl-2 and Bcl-xL
(Gottschalk et al., 1994; Coulson et al., 1999; Yuste et al.,
2002), these studies were all undertaken using cells that
overexpressed these proteins to high levels. Here we have be-
gun to study the subcellular localization of the endogenous
proteins. It will now be crucial to examine whether endoge-
nous Bcl-xL exerts a mitochondria-specific function that can-
not be replaced by Bcl-2, or whether endogenous Bcl-2 reg-
ulates ER-associated events of apoptosis that are not affected
by Bcl-xL. Such organelle-specific actions may include post-
translational modifications such as the recently published
deamidation of Bcl-xL, which inactivates the endogenous
protein in response to DNA damaging agents and does not
occur on Bcl-2 (Deverman et al., 2002). Studies using Bcl-x
and Bcl-2 knockout mice have further shown that these pro-
teins play nonredundant roles in tissues and cells (Veis et al.,
1993; Motoyama et al., 1995). Although this may simply re-
flect a difference in tissue distribution, it could also be a con-
sequence of distinct subcellular localizations and/or molecu-
lar mechanisms to oppose cell death of Bcl-2 and Bcl-xL. To
solve this issue, one would for example need to express Bcl-2
on mitochondria at similar levels as Bcl-xL in a Bcl-x–null
tissue and examine whether this now rescues the knockout
phenotype. Irrespective of the result, the data presented here
improve our understanding of how proteins are specifically
targeted to the MOM and how they differ from proteins
that accumulate on other intracellular membranes.
Materials and methods
cDNAs and site-directed mutagenesis
The cDNAs for human and mouse Bcl-2, human Bax, FLAG-tagged human
Bcl-2, and Bcl-xS and FLAG-tagged Bcl-xS devoid of the last 21 amino ac-
ids (FLAG–Bcl-xS TMB) were generated and subcloned into the pcDNA3
or pcDNAampI vectors (Invitrogen) as previously described (Borner et al.,
1994; Conus et al., 2000a; Lindenboim et al., 2000). The cDNA for human
Bcl-xL was obtained from G. Nunez (University of Michigan, Ann Arbor,
MI) (in pcDNA3). pEF-Bcl-xL–FLAG-puro was a gift from D. Huang (Walter
and Eliza Hall Institute of Medical Research, Melbourne, Australia) (Mori-
ishi et al., 1999). All EGFP constructs were made in the pEGFP-C1, -C2, or
-C3 vectors (Invitrogen) except for TAP(I-VI)–EGFP (EGFP-N3 vector; ob-
tained from J. Neefjes, Netherlands Cancer Institute, Amsterdam, Nether-
lands) (Vos et al., 2000). The cDNAs for the various (FLAG–) Bcl-2 and
Bcl-xL mutants, the Bcl-2/Bcl-xL chimeras, and the EGFP fusion proteins
were generated by PCR as described in the online supplemental material
(available at http://www.jcb.org/cgi/content/full/jcb.200210084/DC1). All
constructs were verified by dideoxynucleotide sequencing.
Protein expression and subcellular fractionation
Human embryonic kidney cells (HEK293) were grown on 100 mm until
 80% confluent and then transfected with 10  g of plasmid DNA using
25  l of Superfect (QIAGEN) as described by the manufacturer. After 3–6
h, the Superfect–DNA complexes were removed and the cells were cul-
tured for another 42 h. 3–5   10
7 HEK293 cells were homogenized in
MSH buffer (210 mM mannitol, 70 mM sucrose, 20 mM Hepes, 1 mM
EDTA, pH 7.4) plus protease inhibitors, and nuclei and cellular debris
were removed by centrifugation at 500 g for 5 min. The post-nuclear su-
pernatant was centrifuged at 5,100 g for 10 min to obtain the crude mito-
chondrial pellet. For further purification, the crude mitochondria were laid
on top of a 1–2 M linear sucrose gradient and centrifuged at 52,000 g for
90 min in a SW41 rotor (Beckman Coulter). Purified mitochondria, which
banded at a region corresponding to 1.4 M sucrose, were carefully col-
lected and diluted to 0.25 M sucrose before centrifugation at 30,000 g for
30 min. The resulting pellets were solubilized in buffer H (20 mM Tris-
HCl, 1 mM EDTA, 1 mM EGTA, 6 mM  -mercaptoethanol, pH 7.5) con-
taining 1% SDS. The band at 1.0 M sucrose, which corresponded to heavy
microsomes, was similarly processed. Centrifugation of the post-mitochon-
drial supernatant at 100,000 g for 60 min yielded the light microsomal pel-
let and the cytosolic supernatant. Cytosols were immediately frozen; light
microsomes were resuspended in buffer H containing 1% SDS. All frac-T
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tions were tested for their purity by immunoblot analysis using antibodies
against organelle-specific proteins.
Submitochondrial fractionation
Fractionation of mitochondria isolated from rat liver or HEK293 cells into
inner membrane, outer membrane, and matrix components was performed
exactly as previously described (Hoppel et al., 1998). Equal amounts of
protein were loaded on SDS gels for anti–Bcl-x immunoblot analysis.
Sodium carbonate extractions
Crude mitochondria or microsomes (as prepared above) were resuspended
in 0.1 M sodium carbonate (pH 12) and incubated for 20 min on ice. After
centrifugation, the supernatant (containing the alkali-extractable proteins)
was titrated to neutral pH with HCl. The pellet (containing the alkali-resis-
tant fraction) was washed three times and then resuspended in buffer H
(see above) containing 1% SDS. About 10% of the crude mitochondria or
microsomal fraction was directly solubilized in buffer H containing 1%
SDS (detergent control).
SDS-PAGE and Western blotting
30  g of protein from subcellular fractions and sodium carbonate extrac-
tions were run on 15% SDS-PAGE, transferred to polyvinylidene difluoride
(PVDF) membrane (BDH), and immunodetected by anti-h/m/rBcl-x (S-18,
1:2,000; Santa Cruz Biotechnology, Inc.), anti–hBcl-2 (clone 124, 1:1,000;
DakoCytomation), anti–mBcl-2 (10C4, 1:1000; Zymed Laboratories), anti-
GFP/JL-8 (Living colors
®, 1:1,000; Invitrogen), anti-KDEL (1:1,000; Stress-
Gen Biotechnologies), anti-grp78/Bip (1:1,000; StressGen Biotechnologies),
and anti-COX/VIc (1:300; Molecular Probes) primary antibodies followed
by peroxidase-coupled, Fc-specific goat anti–rabbit or anti–mouse second-
ary antibodies (Sigma-Aldrich). Immunodetection was performed by ECL
(Pierce Chemical Co.). Equal protein loading was confirmed by amido
black staining of the membrane.
Immunofluorescence analysis
Rat embryo fibroblasts (R6) or human epithelioid cervical carcinoma
(HeLa) cells were grown on 12-mm glass coverslips and then were tran-
siently transfected with 0.8  g of plasmid DNA and 3.2  l of Superfect as
described above. At 24 h after transfection, cells were fixed in 4% parafor-
maldehyde and permeabilized with 0.05% saponin and ice cold acetone.
The cells were incubated with anti-h/m/rBcl-xL (S-18, 1:150; Santa Cruz
Biotechnology, Inc.), anti–hBcl-2 (clone 124, 1:100, DakoCytomation), or
anti–mBcl-2 (10C4, 1:100; Zymed Laboratories) in the presence of either
anti–cytochrome c (1:50; BD Biosciences), anti–TOM-20 (1:300; gift from
B. Hanson, Institute of Molecular and Cell Biology, Singapore), or anti-cal-
nexin (1:100; StressGen Biotechnologies) as colocalization markers for 90
min followed by fluorescein- and/or Texas red–conjugated goat anti–rabbit
or anti–mouse secondary antibodies (Jackson ImmunoResearch Laborato-
ries) for another 60 min. After postfixation in 4% paraformaldehyde con-
taining 2  g/ml Hoechst 33342 dye (Molecular Probes), the anti-fading
agent Slowfade (Molecular Probes) was added, and the cells were viewed
under a ZEISS Axioplan fluorescence microscope using standard filter for
green and red fluorescence. Pictures were taken with a ZEISS digital cam-
era and processed with the ZEISS AxioVision 3.06 software.
In vitro transcription–translation (IVTT)
The TNT Quick T7-coupled reticulocyte lysate system (Promega) was used
essentially as described by the manufacturer. In vitro transcription–transla-
tion (IVTT) was performed at 30 C for 60 min in the presence of 0.6 mCi/ml
[
35S]methionine (Amersham Biosciences) in a volume of 25  l. The reaction
was stopped by the addition of 10  g/ml cycloheximide (CHX). The lysate
was centrifuged for 15 min at 12,000 g to remove possible nonsoluble ag-
gregates. For membrane association–insertion assays, freshly prepared crude
mitochondria and microsomes from HEK293 cells were resuspended in
MSH buffer (pH 7.5). 10  l of the precleared IVTT product was mixed with
25  l of membranes and incubated at 30 C for 20 min. After a centrifuga-
tion step (12,000 g for mitochondria, 100,000 g for microsomes), superna-
tants were collected and the membranes were washed three times in MSH
buffer before analysis by SDS-PAGE and detection by autoradiography. For
alkaline extraction of mitochondria/microsomes carrying IVVT products, the
membranes were treated with sodium carbonate as described above.
Online supplemental material
Details about the generation of the various Bcl-2, Bcl-xL, and EGFP
mutants by PCR can be found a http://www.jcb.org/cgi/content/full/
jcb.200210084/DC1.
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